Zobrazeno 1 - 10
of 98
pro vyhledávání: '"Tetsunari Hase"'
Autor:
Yuichi Ozawa, Yasuhiro Koh, Tetsunari Hase, Kenji Chibana, Kyoichi Kaira, Kyoichi Okishio, Eiki Ichihara, Shuji Murakami, Mototsugu Shimokawa, Nobuyuki Yamamoto
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Background: ALK-tyrosine kinase inhibitors (ALK-TKIs) are effective for treating non-small-cell lung cancer with ALK gene rearrangement; however, resistance is inevitable. Brigatinib is a unique ALK-TKI that is effective against many resistance mutat
Externí odkaz:
https://doaj.org/article/49d4fe358af74383a12fd7f0ddcc1676
Autor:
Takahiro Hatta, Tetsunari Hase, Toru Hara, Tomoki Kimura, Eiji Kojima, Takashi Abe, Yoshitsugu Horio, Yasuhiro Goto, Naoya Ozawa, Naoyuki Yogo, Hirofumi Shibata, Tomoya Shimokata, Tetsuya Oguri, Masashi Yamamoto, Kiyoshi Yanagisawa, Masahiko Ando, Yuichi Ando, Masashi Kondo, Makoto Ishii, Yoshinori Hasegawa
Publikováno v:
Cancer Medicine, Vol 12, Iss 15, Pp 15955-15969 (2023)
Abstract Background The Cockcroft–Gault formula is commonly used as a substitute for glomerular filtration rate (GFR) in Calvert's formula for carboplatin dosing, where adjusting serum creatinine measured using the enzymatic method with 0.2 mg/dL h
Externí odkaz:
https://doaj.org/article/a40d3403fb414a989bb00b6f8030a3d5
Autor:
Hiromasa Tanaka, Daijiro Iwata, Yuki Shibata, Tetsunari Hase, Daisuke Onoshima, Naoyuki Yogo, Hirofumi Shibata, Mitsuo Sato, Kenji Ishikawa, Ikuo Nagasawa, Yoshinori Hasegawa, Makoto Ishii, Yoshinobu Baba, Masaru Hori
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Various liquid biopsy methods have been developed for the non-invasive and early detection of diseases. In particular, the detection of circulating tumor cells (CTCs) and cancer-associated fibroblasts (CAFs) in blood has been receiving a gre
Externí odkaz:
https://doaj.org/article/691b5df5199a459b98fac9e5ddf5e7bd
Autor:
Mei-Chee Tai, Leonidas E. Bantis, Gargy Parhy, Taketo Kato, Ichidai Tanaka, Chi-Wan Chow, Junya Fujimoto, Carmen Behrens, Tetsunari Hase, Koji Kawaguchi, Johannes F. Fahrmann, Edwin J. Ostrin, Kohei Yokoi, Toyofumi F. Chen-Yoshikawa, Yoshinori Hasegawa, Samir M. Hanash, Ignacio I. Wistuba, Ayumu Taguchi
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 4, p 2331 (2024)
Early-stage lung adenocarcinoma (LUAD) patients remain at substantial risk for recurrence and disease-related death, highlighting the unmet need of biomarkers for the assessment and identification of those in an early stage who would likely benefit f
Externí odkaz:
https://doaj.org/article/3935571613464aff8604c12b722b1cf0
Autor:
Soei Gen, Ichidai Tanaka, Masahiro Morise, Junji Koyama, Yuta Kodama, Akira Matsui, Ayako Miyazawa, Tetsunari Hase, Yoshitaka Hibino, Toshihiko Yokoyama, Tomoki Kimura, Norio Yoshida, Mitsuo Sato, Naozumi Hashimoto
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-13 (2022)
Abstract Background Osimertinib—the third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)—has been widely used as a first-line treatment for patients with metastatic EGFR-mutant non-small cell lung cancer (NSCLC
Externí odkaz:
https://doaj.org/article/0a13a5e26a90476f852a18912cc02403
Autor:
Hideki Terai, MD, Kenzo Soejima, MD, Asanao Shimokawa, PhD, Hidehito Horinouchi, MD, Junichi Shimizu, MD, Tetsunari Hase, MD, Ryota Kanemaru, MD, Kana Watanabe, MD, Kiichiro Ninomiya, MD, Naoko Aragane, MD, Noriko Yanagitani, MD, Yoshihiko Sakata, MD, Masahiro Seike, MD, Daichi Fujimoto, MD, Masashi Kasajima, MD, Akihito Kubo, MD, Sojiro Kusumoto, MD, Yoshitaka Oyamada, MD, Keiichi Fujiwara, MD, Masahide Mori, MD, Midori Hashimoto, MD, Masato Shingyoji, MD, Masahiro Kodani, MD, Jin Sakamoto, MD, Toshihiko Agatsuma, MD, Kosuke Kashiwabara, MD, Minehiko Inomata, MD, Motoko Tachihara, MD, Kazuhisa Tanaka, MD, Kenji Hayashihara, MD, Nobuyuki Koyama, MD, Kaoru Matsui, MD, Koichi Minato, MD, Daisuke Jingu, MD, Hiroyuki Sakashita, MD, Satoshi Hara, MD, Tomoyuki Naito, MD, Asuka Okada, MD, Masayuki Tanahashi, MD, Yuki Sato, MD, Koichiro Asano, MD, Takayuki Takeda, MD, Kensuke Nakazawa, MD, Toshiyuki Harada, MD, Kazuhiko Shibata, MD, Tatsuo Kato, MD, Etsuo Miyaoka, PhD, Ichiro Yoshino, MD, Akihiko Gemma, MD, Tetsuya Mitsudomi, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 11, Pp 100404- (2022)
Introduction: Pembrolizumab is a programmed death-ligand 1 inhibitor that was initially indicated for monotherapy in patients with advanced lung cancer. The Japanese Lung Cancer Society conducted an observational study on pembrolizumab using confirma
Externí odkaz:
https://doaj.org/article/67a827674fcd4c4087dafceff77375be
Autor:
Masashi Akiyama, Tomoko Kobayashi, Shintaro Iwama, Yoshinori Yasuda, Norio Okada, Takayuki Okuji, Takeshi Onoue, Motomitsu Goto, Mariko Sugiyama, Taku Tsunekawa, Hiroshi Takagi, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Kenji Yokota, Tetsunari Hase, Naozumi Hashimoto, Masahiko Ando, Yasushi Fujimoto, Hideharu Hibi, Michihiko Sone, Yuichi Ando, Hiroshi Arima
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Background Several immune-related adverse events (irAEs) are reported to be associated with therapeutic efficacy of immune checkpoint inhibitors, yet whether pituitary dysfunction, a life-threatening irAE, affects overall survival (OS) in patients wi
Externí odkaz:
https://doaj.org/article/8191f1e666b742649b4d729b6773268b
Autor:
Masashi Akiyama, Tomoko Kobayashi, Shintaro Iwama, Yoshinori Yasuda, Norio Okada, Takayuki Okuji, Takeshi Onoue, Motomitsu Goto, Mariko Sugiyama, Taku Tsunekawa, Hiroshi Takagi, Daisuke Hagiwara, Hidetaka Suga, Ryoichi Banno, Kenji Yokota, Tetsunari Hase, Naozumi Hashimoto, Masahiko Ando, Yasushi Fujimoto, Hideharu Hibi, Michihiko Sone, Yuichi Ando, Hiroshi Arima
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Externí odkaz:
https://doaj.org/article/3b8a981387264b298db084b2d8e3f0f3
Autor:
Naoyuki Yogo, Tetsunari Hase, Toshihiro Kasama, Keine Nishiyama, Naoya Ozawa, Takahiro Hatta, Hirofumi Shibata, Mitsuo Sato, Kazuki Komeda, Nozomi Kawabe, Kohei Matsuoka, Toyofumi Fengshi Chen-Yoshikawa, Noritada Kaji, Manabu Tokeshi, Yoshinobu Baba, Yoshinori Hasegawa
Publikováno v:
PLoS ONE, Vol 15, Iss 11, p e0241422 (2020)
Detecting molecular targets in specimens from patients with lung cancer is essential for targeted therapy. Recently, we developed a highly sensitive, rapid-detection device (an immuno-wall device) that utilizes photoreactive polyvinyl alcohol immobil
Externí odkaz:
https://doaj.org/article/e78fa9ec500a465f850131750d97f5b3
Autor:
Yutaka Fujiwara, Reiko Makihara, Tetsunari Hase, Naozumi Hashimoto, Tomoyuki Naito, Yukari Tsubata, Takae Okuno, Toshiaki Takahashi, Haruki Kobayashi, Yuki Shinno, Yoshitaka Zenke, Takaya Ikeda, Yukio Hosomi, Kageaki Watanabe, Satoru Kitazono, Naomi Sakiyama, Yoshinori Makino, Noboru Yamamoto
Publikováno v:
Cancer Science. 114:2087-2097